Francesco Giotta

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

Pierfranco Conté, Antonio Frassoldati, Giancarlo Bisagni et al. · Annals of Oncology · 2018 · 152 citations · Full text

Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer

Maria Vittoria Dieci, Pierfranco Conté, Giancarlo Bisagni et al. · Annals of Oncology · 2019 · 94 citations · Full text

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 86 citations · Full text

Endocrine Oncology, Breast Oncology, Medicine +7

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

Giulia Bon, Laura Pizzuti, Valentina Laquintana et al. · Journal of Experimental & Clinical Cancer Research · 2020 · 72 citations · Full text

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience

Patrizia Vici, Laura Pizzuti, Andrea Michelotti et al. · Oncotarget · 2017 · 68 citations · Full text